In addition, the predicted risk scores computed based on the best-performing 5hmC model could stratify patients with grade 4 gliomas into two groups with significant survival differences independent of IDH1 mutations or certain molecular types, suggesting that the 5hmC model captured the molecular characteristics of tumors that are independent of IDH1 mutation status and gene expression-based molecular subtypes. This evidence concerns the gene IDH1 and central nervous system cancer.